Lexaria Bioscience is setting new standards in drug delivery with its patented DehydraTECH™ oral technology, optimizing absorption for GLP-1 and other high-demand drugs.

Lexaria Bioscience’s DehydraTECH™ technology aims to redefine oral drug delivery, focusing on faster absorption and improved efficacy, with a promising impact on the GLP-1 pharmaceutical market.

Lexaria Bioscience is advancing GLP-1 drug delivery, aiming to improve effectiveness and reduce side effects for this fast-growing market.

Sernova's clinical trials for type 1 diabetes have led to multiple patients achieving insulin independence and stable long-term blood sugar levels.